Prehypertension: What is the current status?
AbstractCardiovascular disease (CVD) risk is a continuum across blood pressure. The term prehypertension was introduced becauseit is now recognized that blood pressure readings between what is deemed optimal and hypertension is associated withincreased CVD risk. The prevalence of prehypertension is high and the progression to hypertension is also high.Prehypertension is also commonly associated with other CVD risk factors namely dyslipidaemia, dysgylcaemia and overweight/obesity. Eighty-five percent of prehypertensives have one other or more CVD risk factor compared to normotensives. Arecent study has shown a reduction in the development of hypertension from prehypertension with the use of an angiotensinreceptor blocker. Unfortunately to date, the impact of treatment of prehypertension on CVD outcome is still unknown exceptin those with high CVD risk like diabetes or established CVD. However this does not mean nothing can be done for those withprehypertension. The aim of managing prehypertension is to lower the BP, prevent progression to hypertension and toprevent BP related CVD deaths. Lifestyle changes can reduce BP and this by itself can lower CVD risk. Until more evidenceabout other modalities of treatment become available this is a sensible and cost-effective way to manage prehypertension.
Chobanian AV, Bakris GL, Black HR, et al and the National High Blood Pressure Education Program Coordinating Committee. The seventh report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure. The JNC-7 Report. JAMA. 2003;289(19):2560-72.
Chobanian AV, Bakris GL, Black HR, et al and the National High Blood Pressure Education Program Coordinating Committee. The seventh report of the Joint National Committee on the Prevention, Detection, Evaluation and Treatment of High Blood Pressure. Hypertension. 2003;42(6):1206-52.
JNC-6. National High Blood Pressure Education Program. The sixth report of the Joint National Committee on Prevention, Detection, Evaluation and Treatment of High Blood Pressure. Arch Intern Med. 1997;157:2413-46.
Malaysian Clinical Practice Guidelines: Management of Hypertension, 3rd Edition. February 2008.
Mancia G, De Backer G, Dominiczak A, et al for The Task Force for the Management of Arterial Hypertension of the European Society of Hypertension (ESH) and of the European Society of Cardiology (ESC). 2007 Guidelines for the management of arterial Hypertension. Eur Heart J. 2007;28(12):1462-536.
Wang Y, Wang QJ. The prevalence of prehypertension and hypertension among US adults according to the new Joint National Committee guidelines. Arch Intern Med. 2004;164(19):2126-34.
Lim TO, Ding LM, Goh BL, et al. Distribution of blood pressure in a national sample of Malaysian adults. Med J Malaysia. 2000;55(1):90-107.
Chia YC, Srinivas P. Cardiovascular disease risk in subjects with normal to high normal blood pressure in a developing country. J Hypertension. 2008;26(Suppl 1):S9. Presented in: 18th Scientific Meeting of European Society of Hypertension and ISH 22nd Scientific Meeting International Society of Hypertension, Berlin, Germany. June 2008.
Greenlund KJ, Croft JB, Mensah GA. Prevalence of heart disease and stroke risk factors in persons with prehypertension in the United States, 1999–2000. Arch Intern Med. 2004;164(19):2113-8.
Mainous AG III, Everett CJ, Liszka H, et al. Prehypertension and mortality in a nationally representative cohort. Am J Cardiol. 2004;94(12):1496-500.
Vasan RS, Larson MG, Leip EP, et al. Assessment of frequency of progression to hypertension in non-hypertensive participants in the Framingham Heart Study: a cohort study. Lancet. 2001;358(9294):1682-6.
Trophy Julius S, Nesbitt SD, Egan BM, et al for the Trial of Preventing Hypertension (TROPHY) Study Investigators. Feasibility of treating prehypertension with an angiotensinreceptor blocker. N Eng J Med. 2006;354(16):1685-97.
Liszka HA, Mainous III AG , King DE, et al. Prehypertension and cardiovascular morbidity. Ann Fam Med. 2005;3(4):294-9.
He J, Whelton PK. Elevated systolic blood pressure and risk of cardiovascular and renal disease: overview of evidence from observational epidemiologic studies and randomized controlled trials. Am Heart J. 1999;138(3 Pt 2):211-9.
Lewington S, Clarke R, Qizilbash N, et al. Age-specific relevance of usual blood pressure to vascular mortality: a metaanalysis of individual data for one million adults in 61 prospective studies. Lancet. 2002;360(9349):1903-13.
Russell LB, Valiyeva E, Carson JL. Effects of prehypertension on admissions and deaths: a simulation. Arch Intern Med. 2004;164(19):2119-24.
Washio M, Tokunaga S, Yoshimasu K, et al. Role of prehypertension in the development of coronary atherosclerosis in Japan. J Epidemiol. 2004;14(2):57-62.
Toikka JO, Laine H, Ahotupa M, et al. Increased arterial intimamedia thickness and in vivo LDL oxidation in young men with borderline hypertension. Hypertension. 2000;36(6):929-33.
King DE, Egan BM, Mainous AG III, Geesey ME. Elevation of C-reactive protein in people with prehypertension. J Clin Hypertens. 2004;6(10):562-8.
Chrysohoou C, Pitsavos C, Panagiotakos DB, et al. Association between prehypertension status and inflammatory markers related to atherosclerotic disease: the ATTICA Study. Am J Hypertens. 2004;17(7):568-73.
Lee JE, Kim YG, Choi YH, et al. Serum uric acid is associated with microalbuminuria in prehypertension. Hypertension. 2006;47(5):962-7.
The effects of nonpharmacologic interventions on blood pressure of persons with high normal levels. Results of the Trials of Hypertension Prevention, phase I. JAMA. 1992;267(9):1213-20.
Karanja NM, Obarzanek E, Lin PH, et al. Descriptive characteristics of the dietary patterns used in the Dietary Approaches to Stop Hypertension Trial. DASH Collaborative Research Group. J Am Diet Assoc. 1999;99(8 Suppl):S19-S27.
Whelton PK, Appel LJ, Espeland MA, et al. Sodium restriction and weight loss in the treatment of hypertension in older persons: A randomised controlled trial of non- pharmacologic interventions in the elderly (TONE). JAMA. 1998;279(11):839-46.
Neter JE, Stam BE, Kok FJ, et al. Influence of weight reduction on blood pressure: a meta-analysis of randomized controlled trials. Hypertension. 2003;42(5):878-84.
Stevens VJ, Obarzanek E, Cook NR, et al and Trials of Hypertension Prevention Research Group. Long-term weight loss and changes in blood pressure: results of the Trials of Hypertension Prevention, phase II. Ann Intern Med. 2001;134(1):1-11.
TOHP 2-The Trials of Hypertension Prevention Collaborative Research Group. Effects of weight loss and sodium reduction intervention on blood pressure and hypertension incidence in overweight people with high normal blood pressure: the Trials of Hypertension Prevention, phase II. Arch Intern Med. 1997;157(6):657-67.
He J, Whelton PK, Appel LJ, et al. Long-term effects of weight loss and dietary sodium reduction on incidence of hypertension. Hypertension. 2000;35(2):544-9.
Cutler JA, Follman D, Allender PS. Randomized trials of sodium reduction: an overview. Am J Clin Nutr. 1997;65(2 Suppl):S643-S651.
Ainsworth BE, Keenan NL, Strogatz DS, et al. Physical activity and hypertension in black adults: the Pitt County Study. Am J Public Health. 1991;81(11):1477-9.
Reaven PD, Barrett-Connor E, Edelstein S. Relation between leisure time physical activity and blood pressure in older women. Circulation. 1991;83(2):559-65.
Braith RW, Pollock ML, Lownthal DT, et al. Moderate and highintensity exercise lowers blood pressure in normotensive subjects 60 to 79 years of age. Am J Cardiol. 1994;73(15):1124-8.
Hagberg JM, Montain SJ, Martin WH, Ehsani AA. Effect of exercise training in 60- to 69-year-old persons with essential hypertension. Am J Cardiol. 1989;64(5):348-53.
Puddey IB, Beilin LJ, Vandongen R, et al. Evidence for a direct effect of alcohol consumption on blood pressure in normotensive men: a randomized controlled trial. Hypertension. 1985;7(5):707-13.
Xin X, He J, Frontini MG, et al. Effects of alcohol reduction on blood pressure: a meta-analysis of randomized controlled trials. Hypertension. 2001;38(5):1112-7.
Hansson L, Zanchetti A, Carruthers SG, et al. Effects of intensive blood pressure lowering and low-dose aspirin in patients with hypertension: principal results of the Hypertension Optimal Treatment (HOT) randomized trial. Lancet. 1998;351(9118):1755-62.
Heart Outcomes Prevention Evaluation (HOPE) Study Investigators. Effects of an angiotensin-converting-enzyme inhibitor, ramipril, on cardiovascular events in high-risk patients. N Engl J Med. 2000;342(3):145-53.
PROGRESS Collaborative Group. Randomised trial of perindopril based blood pressure-lowering regimen among 6105 individuals with previous stroke or transient ischaemic attack. Lancet. 2001;358(9287):1033-41.
Nissen SE, Tuzcu E., Libby P, et al for the CAMELOT Investigators. Effect of antihypertensive agents on cardiovascular events in patients with coronary disease and normal blood pressure: The CAMELOT Study: a randomized controlled trial. JAMA. 2004;292(18):2217-26.